Biohaven Ltd. Operating Expenses
Biohaven Ltd. (BHVN) reported Operating Expenses of $567.93 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued
us-gaap:OperatingExpenses · last filed 2023-03-23
- Biohaven Ltd. operating expenses for fiscal 2022 was $567.93M, a 159.45% increase from fiscal 2021.
- Biohaven Ltd. operating expenses for fiscal 2021 was $218.90M, a 91.17% increase from fiscal 2020.
- Biohaven Ltd. operating expenses for fiscal 2020 was $114.51M.
| Period end | Operating Expenses 12 month |
|---|---|
| 2022-12-31 | $567.93M 10-K · filed 2023-03-23 |
| 2021-12-31 | $218.90M 10-K · filed 2023-03-23 |
| 2020-12-31 | $114.51M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |